Repligen Announces Acquisition of BioLife for $11.25 + 0.1442 Shares

What Happened

• Repligen Corporation and BioLife Solutions entered into a definitive Agreement and Plan of Merger on July 21, 2026, approved by the boards of both companies. Under the deal each outstanding share of BioLife common stock will be converted into $11.25 in cash plus 0.1442 shares of Repligen common stock (no fractional shares; cash paid in lieu). The transaction will be effected in a two-step merger (Merger Sub 1 into BioLife, then BioLife into Merger Sub 2) and is expected to close in the fourth quarter of 2026, subject to customary conditions and approvals.
• Repligen also announced preliminary financial results for the quarter ended June 30, 2026 (press release and presentation are attached as exhibits). Repligen provided employee FAQs and the CEO sent an internal notice to employees; both documents are filed as exhibits.

Key Details

• Deal consideration per BioLife share: $11.25 cash + 0.1442 Repligen shares.
• Closing conditions include BioLife stockholder approval, effectiveness of Repligen’s Form S-4 (proxy/prospectus), HSR/antitrust clearance, Nasdaq listing approval for the Repligen shares to be issued, and absence of material adverse effects.
• Treatment of equity awards: BioLife options, RSUs, PSUs and restricted stock awards will vest/settle and convert into the merger consideration at closing (with customary tax withholdings).
• Termination/fee: BioLife may owe a $59,000,000 termination fee to Repligen in specified circumstances if BioLife accepts a superior proposal after certain events.

Why It Matters

• This is a material acquisition for Repligen that combines BioLife’s cell-processing tools business with Repligen’s offerings; the companies expect the transaction to be financially compelling and accretive in the near term per their statements.
• The deal requires shareholder and regulatory approvals and an effective S-4/proxy statement; these steps introduce execution risk and timing uncertainty (expected close Q4 2026).
• Investors should note potential dilution from the stock consideration, the $59M breakup fee exposure, accelerated vesting of BioLife equity awards, and general integration and regulatory risks disclosed in the filing. Repligen and BioLife filed forward-looking cautionary statements and will mail a definitive proxy/prospectus to BioLife stockholders when available.